A phase I clinical trial is now open and it is recruiting refractory CLL patients to evaluate the efficacy of anti-ROR1 CAR T cells in CLL (ClinicalTrials.gov Identifier: NCT02706392). Here, ROR1 is linked to B-cell chronic lymphocytic leukemia.